T1	Participants 66 130	HIV-infected adults with a toll-like receptor 9 agonist adjuvant
T2	Participants 1197 1221	Ninety-seven participant
T3	Participants 1311 1391	experimental group (n = 48) than among controls (n = 49; 48.8% vs 25.0%; P = .02
